News – Page 920 – Endpoints News

Nkarta maps out clinical, manufacturing plans for CAR-NK following $114M round led by Samsara

6 years ago

George Scangos heads back to Wall Street. And he’s bringing along some of the best connections in biotech

6 years ago

US judge paves way for branded and generic opioid makers to face landmark October trial

6 years ago

In the midst of a deal spree, Bayer turns to veteran J&J dealmaker Marianne De Backer to bring home the technology

6 years ago

Bellus hopes to fuel up on IPO cash as it squares off with giant Merck on a rival drug

6 years ago

Armed with promising alopecia PhII, Concert edges forward with modified JAK inhibitor — but safety will still be ...

6 years ago

Syncona dives deep into dry AMD R&D, upping Gyroscope bet to $100M

6 years ago

Ardelyx's lead drug tenapanor scores in second hyperphosphatemia study, shares leap

6 years ago

A PhII flop triggers an ugly rout for micro-cap biotech Aridis; Genfit CEO passes baton to successor

6 years ago

AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study

6 years ago

Vertex gambles $950M on biotech buyout, hunting a cure for diabetes

6 years ago

AI study led by Insilico's Alex Zhavoronkov bolsters case for faster, cheaper drug discovery

6 years ago

Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?

6 years ago

RA Capital-backed cell therapy player in the neoantigen game grabs a $121M megaround to fund first human studies

6 years ago

Once again Novartis’ cardio team looks to beat the odds using sketchy data and a familiar argument

6 years ago

A new PCSK9 player draws rave reviews for inclisiran. Can a marketing war with Amgen be far behind?

6 years ago

Alexion hit by surprise inter partes review as Amgen challenges Soliris patents

6 years ago

Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties

6 years ago

Azar keen on nominating Brett Giroir, divisive assistant HHS secretary, to top job at FDA — report

6 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

6 years ago

Ex-Altimmune chief Bill Enright lands CEO role at Vaccitech; Reata poaches Alnylam CFO Manmeet Soni

6 years ago

Remember that post-marketing trial? New study confirms many drugmakers don’t do them — half drag their feet

6 years ago

On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO

6 years ago

Mylan wins tentative US approval for generic version of Lilly's Alimta — it could be years before it can be sold

6 years ago

First page Previous page 917 918 919920921 922 923 Next page Last page